Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurimmune AG

www.neurimmune.com

Latest From Neurimmune AG

Coronavirus Update: Searching For A Treatment

Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies

Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts. 

Coronavirus COVID-19 Clinical Trials

Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates

The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.

Business Strategies Research and Development Strategies

BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Neurimmune Therapeutics AG
  • Neurimmune Holdings AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Neurimmune AG
  • Senior Management
  • Roger Nitsch, Pres. & CEO
    Dirk Schimkat, CFO
    Jan Grimm, PhD, CSO
    Fabian Buller, CBO
    Christoph Hock, MD, CMO
    Michael Salzmann, PhD, COO
  • Contact Info
  • Neurimmune AG
    Phone: (41) 44 755 4646
    Wagistrasse 13
    Schlieren-Zurich, CH-8952
    Switzerland
UsernamePublicRestriction

Register